PALI — Palisade Bio, Inc.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ Capital Market
- Employees: 8
- Website: https://www.palisadebio.com
Latest SEC filings for PALI
- 8-K — 2026-08-10
- 10-Q — 2026-08-10
- 8-K — 2026-06-11
- S-8 — 2026-06-10
- EFFECT — 2026-05-22
- SCHEDULE 13G — 2026-05-15
- SCHEDULE 13G/A — 2026-05-15
- 10-Q — 2026-05-12
- S-3 — 2026-05-12
- 8-K — 2026-05-12
Latest PALI news
- — Palisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at ACG 2026 (globenewswire.com)
- — Palisade Bio, Inc. (NASDAQ:PALI) Stock Has Average Target Price of $9.83 According to Analysts
- — Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn's Disease at UEG Week 2026 (globenewswire.com)
- — Palisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn’s
- — Palisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn's (marketbeat.com)
Educational tool only — not investment advice.